法国老年人应避免的抗胆碱能或镇静药物使用 prevalence 研究
本研究利用法国国家健康数据系统(SNDS)的匿名数据,纳入2023年全年1693万余名65岁及以上老年人,依据2023 AGS Beers Criteria和REMEDI[e]S工具识别应避免的抗胆碱能或镇静药物。结果显示总体使用率为32.8%,养老机构内达54.5%,提示此类药物仍被频繁处方。
要点
- 2023年法国65岁及以上人群中32.8%被配发应避免的抗胆碱能或镇静药物。
- 养老机构居住者使用率54.5%,明显高于居家者的32.1%。
- 最常配发者为奥沙西泮、阿普唑仑、佐匹克隆等,提示去处方需求迫切。
核心结论
- 尽管潜在不适当用药(PIM)标准不断更新,法国老年人应避免的抗胆碱能或镇静药物仍被频繁处方。
- 未来需评估此类用药是否导致老年人结局恶化,并推动处方者和药师开展去处方。
研究设计与样本
- 纳入全部65岁及以上人群,共16,938,152人,55%为女性。
- 按年龄(65-84岁与85岁及以上)和居住地(居家与机构)分亚组评估使用率。
主要发现
- 总体使用率为32.8%;65-84岁为32.3%,85岁及以上为34.8%。
- 居家者使用率32.1%,机构居住者54.5%。
- 人群中79.8%为65-84岁,20.2%为85岁及以上;97.0%居家,3.0%机构居住。
- 最常配发的药物包括奥沙西泮(5.27%)、阿普唑仑(5.27%)、佐匹克隆(4.85%)、溴西泮(4.23%)。
- 其他较常见者包括甲哌丙嗪(2.88%)、帕罗西汀(2.70%)、奈福泮(2.57%)和羟嗪(2.17%)。
关键数值与推荐
- 抗胆碱能或镇静药物依据2023年美国老年医学会Beers标准(AGS Beers Criteria)和REMEDI[e]S工具中的PIM标准识别。
- 使用率以患者数量和百分比表示,按年龄和居住地亚组报告。
临床怎么用
- 老年医学科医生应常规审查65岁及以上患者的抗胆碱能与镇静药物,尤其关注养老机构居住者。
- 可参照2023 AGS Beers Criteria和REMEDI[e]S工具识别应避免药物,并与药师协作推进去处方。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In older people, medications with anticholinergic or sedative properties are associated with falls, frailty, and functional and cognitive impairment. These medications are often described as a subset of potentially inappropriate medications (PIMs). We examined the prevalence of anticholinergic or sedative medications to avoid in older people in France in 2023. METHODS: This cross-sectional study used anonymized data from a large electronic healthcare database, the French National Health Data System (Système National des Données de Santé, SNDS). All people aged 65 years or older from January 1, 2023, to December 31, 2023, were included in this study. Dispensations of anticholinergic and sedative medications were identified according to PIM criteria (2023 American Geriatrics Society Beers Criteria and REMEDI[e]S tool). The prevalence of anticholinergic or sedative medications was assessed for the study population and by age (65-84 and 85 or older) and living place (home and institutionalized patients) subgroups in terms of number and percentage of patients. RESULTS: This study included 16,938,152 patients aged 65 years or older (55% women). Among all patients, 79.8% were aged between 65 and 84 years and 20.2% were aged 85 years or older. Most patients lived at home (97.0%), and 3.0% were institutionalized. The prevalence of anticholinergic or sedative medications was 32.8% among all patients, 32.3% among 65-84 patients, and 34.8% among 85 or older patients, 32.1% among home patients, and 54.5% among institutionalized patients. The most commonly dispensed anticholinergic or sedative medications were oxazepam (5.27%), alprazolam (5.27%), zopiclone (4.85%), bromazepam (4.23%), metopimazine (2.88%), paroxetine (2.70%), nefopam (2.57%), and hydroxyzine (2.17%). CONCLUSIONS: This study highlighted that anticholinergic and sedative medications to avoid in older people are still frequently prescribed despite the development and regular updating of PIM criteria. Future studies are needed to assess whether this has led to worsened outcomes among older adults who utilized these medications, and new initiatives should be developed to further promote deprescribing by prescribers and pharmacists.
引用
- Novais T, Garnier-Crussard A, Reallon E, et al. Assessing the prevalence of anticholinergic and sedative medications to avoid in older adults from the French Health Data System. J Am Geriatr Soc. 2025. PMID: 39749945. doi:10.1111/jgs.19324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。